RXDX — Prometheus Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $9.56bn
- $8.85bn
- $6.81m
Annual cashflow statement for Prometheus Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.79 | -16.7 | -31.1 | -90.2 | -142 |
| Depreciation | |||||
| Non-Cash Items | 0.069 | -3.17 | 4.34 | 13.6 | 19 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.622 | -0.334 | -1.33 | 12.8 | -1.18 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -6.1 | -20.2 | -28 | -63.5 | -123 |
| Capital Expenditures | -0.082 | -0.279 | -0.204 | -1.14 | -2.7 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 8.21 | -0.859 | 0 | -401 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.082 | 7.93 | -1.06 | -1.14 | -404 |
| Financing Cash Flow Items | 0 | -0.075 | -1.48 | -17.3 | -32.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10.1 | 9.76 | 79.9 | 268 | 562 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.96 | -2.51 | 50.8 | 203 | 35.2 |